Mira Jung
Fondateur chez SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Fortune : 568 907 $ au 31/05/2024
Profil
Mira Jung is the founder of Shuttle Pharmaceuticals, Inc. (founded in 2012) and Shuttle Pharmaceuticals Holdings, Inc. (founded in 2012) where she holds the title of Scientific Director and Chief Scientific Officer-Biology respectively.
Dr. Jung also worked as a Professor at Georgetown University School of Medicine.
She obtained her graduate and doctorate degrees from the University of Kansas.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/03/2024 | 1 071 388 ( 6,38% ) | 568 907 $ | 31/05/2024 |
Postes actifs de Mira Jung
| Sociétés | Poste | Début |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Fondateur | 18/12/2012 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Fondateur | 01/12/2012 |
Anciens postes connus de Mira Jung
| Sociétés | Poste | Fin |
|---|---|---|
| Georgetown University School of Medicine | Corporate Officer/Principal | - |
Formation de Mira Jung
| University of Kansas | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
